US equities |
NVDA $237.05 ▲+1.33% SPCX $165.46 ▲+4.09% MU $1,058.71 ▼-1.51% TSLA $376.45 ▲+1.58% MSFT $527.60 ▲+1.95% INTC $115.94 ▼-2.84% SNDK $1,717.19 ▼-0.16% AMD $627.32 ▼-1.04%
FinancialContent

Articles published by Alector, Inc.

< Previous 1 2 Next >
News headline image
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in the Bank of America CNS Therapeutics Conference
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC GSK
News headline image
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
News headline image
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC GSK
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
< Previous 1 2 Next >